MACROGENICS, INC. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
MACROGENICS, INC. (MGNX) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $202.69 million as of 2017-03-31, per its 10-Q filed 2017-05-03.
Discontinued › Notes › Investments › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2018-02-27
- 2017-03-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $202.69M.
- 2016-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $192.99M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2017-03-31 | $202.69M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $192.99M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |